Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
83%(5 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_3
3
50%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 33 (50.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Study to Compare the Efficacy and Safety of F-627 and GRAN®

NCT04174599
completedphase_1

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02527746
completedphase_3

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT03252431
completedphase_3

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02872103
completedphase_2

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT01648322
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04174599Phase 3

Study to Compare the Efficacy and Safety of F-627 and GRAN®

Completed
NCT02527746Phase 1

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
NCT03252431Phase 3

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
NCT02872103Phase 3

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
NCT01648322Phase 2

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
NCT02521441Phase 2

A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6